The progressive myoclonus epilepsies

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The progressive myoclonus epilepsies (PME) are neurodegenerative diseases with prominent myoclonus and epilepsy. They are mostly, though not exclusively, diseases of children, and are mostly, though not exclusively, fatal. This review includes only those PME where more than one family has been described. The largest group of PME is the neuronal ceroid lipofuscinoses (NCL). The genetics of the NCL is representative of the larger group. Most, but not all, are monogenic, autosomal recessive inherited diseases, and most diseases genes, but not all, encode lysosomal proteins. One of the major questions in PME is "why PME"? That is, why do these neurodegenerative diseases result in so much epileptogenesis? Perhaps, the answers to "why epilepsy?" underlying this entire volume on genetics of epilepsy, will be aided by this group of the severest of epilepsies, where most, probably almost all, genes are already known. As therapies go, while not much is available yet, most of the PME start from a point of initial normalcy, and have a period of minimal symptoms close to onset, and most are relatively simple metabolic diseases. Hence, among the intractable epilepsies, hope for treatments and cures is likely the strongest in this group of diseases.

Original languageEnglish (US)
Pages (from-to)113-122
Number of pages10
JournalProgress in Brain Research
Volume213
Issue numberC
DOIs
StatePublished - Jan 1 2014

Fingerprint

Progressive Myoclonic Epilepsy
Neuronal Ceroid-Lipofuscinoses
Epilepsy
Neurodegenerative Diseases
Hope
Myoclonic Epilepsy
Metabolic Diseases
Genes
Therapeutics

Keywords

  • Batten
  • Gaucher
  • GOSR2
  • Kuf
  • Lafora
  • Mitochondrial
  • Sialidosis
  • Unverricht

ASJC Scopus subject areas

  • Neuroscience(all)
  • Medicine(all)

Cite this

The progressive myoclonus epilepsies. / Minassian, Berge A.

In: Progress in Brain Research, Vol. 213, No. C, 01.01.2014, p. 113-122.

Research output: Contribution to journalArticle

@article{2ecba827f7054006974f415ff97a182d,
title = "The progressive myoclonus epilepsies",
abstract = "The progressive myoclonus epilepsies (PME) are neurodegenerative diseases with prominent myoclonus and epilepsy. They are mostly, though not exclusively, diseases of children, and are mostly, though not exclusively, fatal. This review includes only those PME where more than one family has been described. The largest group of PME is the neuronal ceroid lipofuscinoses (NCL). The genetics of the NCL is representative of the larger group. Most, but not all, are monogenic, autosomal recessive inherited diseases, and most diseases genes, but not all, encode lysosomal proteins. One of the major questions in PME is {"}why PME{"}? That is, why do these neurodegenerative diseases result in so much epileptogenesis? Perhaps, the answers to {"}why epilepsy?{"} underlying this entire volume on genetics of epilepsy, will be aided by this group of the severest of epilepsies, where most, probably almost all, genes are already known. As therapies go, while not much is available yet, most of the PME start from a point of initial normalcy, and have a period of minimal symptoms close to onset, and most are relatively simple metabolic diseases. Hence, among the intractable epilepsies, hope for treatments and cures is likely the strongest in this group of diseases.",
keywords = "Batten, Gaucher, GOSR2, Kuf, Lafora, Mitochondrial, Sialidosis, Unverricht",
author = "Minassian, {Berge A.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/B978-0-444-63326-2.00006-5",
language = "English (US)",
volume = "213",
pages = "113--122",
journal = "Progress in Brain Research",
issn = "0079-6123",
publisher = "Elsevier",
number = "C",

}

TY - JOUR

T1 - The progressive myoclonus epilepsies

AU - Minassian, Berge A.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The progressive myoclonus epilepsies (PME) are neurodegenerative diseases with prominent myoclonus and epilepsy. They are mostly, though not exclusively, diseases of children, and are mostly, though not exclusively, fatal. This review includes only those PME where more than one family has been described. The largest group of PME is the neuronal ceroid lipofuscinoses (NCL). The genetics of the NCL is representative of the larger group. Most, but not all, are monogenic, autosomal recessive inherited diseases, and most diseases genes, but not all, encode lysosomal proteins. One of the major questions in PME is "why PME"? That is, why do these neurodegenerative diseases result in so much epileptogenesis? Perhaps, the answers to "why epilepsy?" underlying this entire volume on genetics of epilepsy, will be aided by this group of the severest of epilepsies, where most, probably almost all, genes are already known. As therapies go, while not much is available yet, most of the PME start from a point of initial normalcy, and have a period of minimal symptoms close to onset, and most are relatively simple metabolic diseases. Hence, among the intractable epilepsies, hope for treatments and cures is likely the strongest in this group of diseases.

AB - The progressive myoclonus epilepsies (PME) are neurodegenerative diseases with prominent myoclonus and epilepsy. They are mostly, though not exclusively, diseases of children, and are mostly, though not exclusively, fatal. This review includes only those PME where more than one family has been described. The largest group of PME is the neuronal ceroid lipofuscinoses (NCL). The genetics of the NCL is representative of the larger group. Most, but not all, are monogenic, autosomal recessive inherited diseases, and most diseases genes, but not all, encode lysosomal proteins. One of the major questions in PME is "why PME"? That is, why do these neurodegenerative diseases result in so much epileptogenesis? Perhaps, the answers to "why epilepsy?" underlying this entire volume on genetics of epilepsy, will be aided by this group of the severest of epilepsies, where most, probably almost all, genes are already known. As therapies go, while not much is available yet, most of the PME start from a point of initial normalcy, and have a period of minimal symptoms close to onset, and most are relatively simple metabolic diseases. Hence, among the intractable epilepsies, hope for treatments and cures is likely the strongest in this group of diseases.

KW - Batten

KW - Gaucher

KW - GOSR2

KW - Kuf

KW - Lafora

KW - Mitochondrial

KW - Sialidosis

KW - Unverricht

UR - http://www.scopus.com/inward/record.url?scp=84926318511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926318511&partnerID=8YFLogxK

U2 - 10.1016/B978-0-444-63326-2.00006-5

DO - 10.1016/B978-0-444-63326-2.00006-5

M3 - Article

C2 - 25194486

AN - SCOPUS:84926318511

VL - 213

SP - 113

EP - 122

JO - Progress in Brain Research

JF - Progress in Brain Research

SN - 0079-6123

IS - C

ER -